Hansoh Pharma and Roche entered a second antibody drug conjugate collaboration covering two undisclosed Hansoh preclinical programs and multiple Roche-proposed targets using Hansoh’s proprietary ADC platform. Hansoh will receive $400 million upfront and $110…
Pyxis Oncology reported updated Phase I monotherapy data for micvotabart pelidotin, or MICVO, in second-line or later recurrent or metastatic head and neck squamous-cell carcinoma. Among 33 efficacy-evaluable patients treated at 5.4 mg/kg every…
Genentech licensed DualityBio’s DUPAC antibody-drug conjugate platform in a deal worth $45 million upfront and more than $1 billion in potential milestones, gaining rights to a novel-payload ADC technology still in early, DualityBio-led preclinical-to-Phase…
